AbbVie drops IBS drug Viberzi in Canada, 'devastating' patients - Endpoints News

[Health Reporter]

Scoop: AbbVie drops IBS drug Viberzi in Canada, 'devastating' patients  Endpoints News

AbbVie has since confirmed to Endpoints that it is discontinuing Viberzi in Canada this year “as a result of our regular business prioritization review.” The drug will continue to be available in the US, as well as the UK — where Sam lives —  with “no plans to discontinue,” a spokesperson said. It had already been discontinued in the EU back in 2020 at the request of Allergan, the drug’s initial manufacturer before the $63 billion AbbVie buyout that year.

The pharma company declined to offer further explanation of its reasoning behind the discontinuation, adding that there “are alternative therapies available for patients.”

View the full article

[Jeffrey Roberts]

Update:

Allergan Canada and/or Abbvie are considering providing continued access to Viberzi in Canada due to the number of calls that patients have been making to the Allergan Customer Care center.

Patients can contact them 800-668-6424 or MR-GENERAL_INQUIRY@allergan.com